Shingles Vaccine Market - Trends, Outlook, and
Opportunity Analysis, 2018-2026
The shingles vaccine market revenue is expected to grow at a robust rate over the forecast
period. Shingles, also known as herpes zoster, is a viral infection that affects the cranial nerves
that originate in the brain. It is caused by the varicella zoster virus, the same virus that also
cases chicken pox. The virus can stay dormant for many years in the human body. Therefore,
anyone who has had chicken pox in the past is at the risk of developing shingles. According to
the Center for Disease Control and Prevention (CDC), there are an estimated one million cases
of shingles reported every year in the U.S. Moreover, CDC states that around one in every three
people in the U.S. will develop shingles in their lifetime. The risk of shingles increases with
age, with most cases reported among people over 40 years old. This is mainly due to
weakening of the immune system on account of increased stress and inadequate intake of
essential nutrients to keep immunity strong.
For In depth Information Get Sample Copy of this Report @ https://bit.ly/2Nu4SMn
Symptoms include skin rashes, nerve pain, vision loss, chills, upset stomach, muscle weakness,
skin infection, and scarring. Treatment for shingles includes antiviral medication—acyclovir,
valacyclovir, and famciclovir. These medicines help shorten the length and alleviate the severity
of the illness. Further, analgesics may help relieve the pain.
Shingles Vaccine Market Dynamics:
There is a safe and effective vaccines available for preventing shingles. The Zostavax vaccine
licensed by Merck & Co., Inc. in 2006 is an effective vaccine against shingles. The vaccine is
intended for use in population over 50 years of age. The trials of the Zostavax vaccine
demonstrated that the vaccine was 64% effective in people aged 60 to 69 years. The
effectiveness reduces with increasing age i.e. to 41% for the 70–79 age group, and 18% for
those 80 years of age and older. The vaccine was launched in the India market in February
2016, at half the price of the U.S. market. Zostavax, among the only shingles vaccine in the
market, recorded sales of US$ 749 million in 2015.